Press Release: Akoya Biosciences Reports Third Quarter 2024 Financial Results

Dow Jones11-15

(in thousands) 

 
 
                    Three months ended        Nine months ended 
                 ------------------------  ------------------------ 
                  September    September    September    September 
                     30,          30,          30,          30, 
                    2024         2023         2024         2023 
                 -----------  -----------  -----------  ----------- 
Operating 
 expenses         $  20,073    $   26,827   $  74,507    $   87,914 
Impairment               --            --      (2,971)           -- 
Restructuring        (1,690)           --      (3,087)           -- 
                     ------       -------      ------       ------- 
Non-GAAP 
 operating 
 expenses         $  18,383    $   26,827   $  68,449    $   87,914 
                     ======       =======      ======       =======

AKOYA BIOSCIENCES, INC. AND SUBSIDIARY

Loss From Operations to Non-GAAP Loss From Operations Reconciliation (unaudited)

(in thousands) 

 
 
                     Three months ended      Nine months ended 
                   ----------------------  ---------------------- 
                    September   September  September   September 
                       30,         30,        30,         30, 
                      2024        2023       2024        2023 
                   -----------  ---------  ---------  ----------- 
Loss from 
 operations         $  (8,349)  $(11,551)  $(41,018)  $(48,229) 
Provision for 
excess and 
obsolete 
inventories - 
product 
discontinuation 
and lease exit 
inventory 
charges                    --         --      2,045         -- 
Impairment                 --         --      2,971         -- 
Restructuring           1,690         --      3,087         -- 
                       ------    -------    -------    ------- 
Non-GAAP loss 
 from operations    $  (6,659)  $(11,551)  $(32,915)  $(48,229) 
                       ======    =======    =======    ======= 
 
Investor Contact: 
 
Priyam Shah 
investors@akoyabio.com 
 
Media Contact: 
 
Christine Quern 
media@akoyabio.com

(END) Dow Jones Newswires

November 14, 2024 16:00 ET (21:00 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment